Drug Approval | August 31, 2025
FDA suspends Valneva’s license of chikungunya vaccine IXCHIQ in US
The sudden subsequent decision to suspend IXCHIQ is based on updated VAERS data
The sudden subsequent decision to suspend IXCHIQ is based on updated VAERS data
The agency concluded that for people of all ages, IXCHI should be administered when there is a significant risk of chikungunya infection
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus
Test delivers results in just 18 minutes, enabling faster laboratory workflows and patient management during outbreaks
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
Organization to provide vaccinations & treatments for several monsoon related diseases and illnesses across all 102 clinics
States urged to maintain a state of constant vigil through screening of pregnant women for Zika virus infection and monitoring the growth of foetus of expecting mothers who tested positive for Zika
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
India is committed to eliminating Lymphatic Filariasis by 2027, three years ahead of the global target through mission mode, multi partner, multi sector targeted drive
Subscribe To Our Newsletter & Stay Updated
